Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.48 |
| ▸ | JAK1 | P23458 | 2/20 | 0.48 |
| ▸ | TYK2 | P29597 | 2/20 | 0.48 |
| ▸ | JAK3 | P52333 | 2/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PRCP | P42785 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2730004 | 0.92 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19MAPK1 | |
| SCHEMBL10228212 | 0.92 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19MAPK1 | |
| SCHEMBL7888756 | 0.91 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19MAPK1 | |
| SCHEMBL2729426 | 0.91 | TAAR1 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19MAPK1 | |
| Hydrochloric Acid SCHEMBL3708310 | 0.90 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19MAPK1 | |
| SCHEMBL2729791 | 0.88 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9ACYP2C19MAPK1 | |
| SCHEMBL26510682 | 0.87 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL15134851 | 0.87 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19MAPK1 | |
| SCHEMBL2728331 | 0.87 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9ACYP2C19MAPK1 | |
| Hydrochloric Acid SCHEMBL20986624 | 0.87 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9ACYP2C19MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-9273028-B2 | Heterocyclic tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273028-B2 | Heterocyclic tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273028-B2 | Heterocyclic tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20130345192-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| EP-2632898-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | Biogen Idec MA Inc. (US) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012058645-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012058645-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | TEC, ABL1, LCK | SMN1; SMN2 4612/4885NPC1 4673/4885RAB9A 1906/4885 |
| US-20130345192-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | TEC, ABL1, LCK | SMN1; SMN2 4612/4885NPC1 4673/4885RAB9A 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.